Cancer Research Technology (CRT) is pleased to announce a major drug discovery feasibility study with Merck Serono, the biopharmaceutical business of Merck, focused on the role of the Hippo pathway in cancer.
Under normal circumstances the Hippo pathway regulates cell size, controlling the growth of tissues during development and regeneration. Deregulation of the Hippo pathway has been implicated in inducing tumours in a broad range of cancers, making it a potentially attractive target for cancer therapy.
Scientists from CRT Discovery Laboratories (CRT-DL) will work together with Merck Serono scientists to validate the target, using CRT-DL’s expertise in building cell screening assays.
The establishment of this relationship exemplifies CRT-DL’s drug discovery model of bringing together complementary skills from academia and industry to build on novel insights within an exciting area of biology, which we hope will lead to new therapies for cancer patients.